312736-49-5

Basic information

• Product Name: 3,5-Dichloropyrazine-2-carboxyamide
• Synonyms: 3,5-Dichloropyrazine-2-carboxyamide;2-Carboxy-3,5-dichloropyrazine;2-COOH-3,5-di-Cl-pyrazine
• CAS NO: 312736-49-5
• Molecular Formula: C₅H₂Cl₂N₂O₂
• Molecular Weight: 192.99
• Product Categories: Nitrogen cyclic compounds
• Mol File: 312736-49-5.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 335.1±37.0 °C(Predicted)
• Appearance: /
• Density: 1.718±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.21±0.28(Predicted)
• CAS DataBase Reference: 3,5-Dichloropyrazine-2-carboxyamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dichloropyrazine-2-carboxyamide(312736-49-5)
• EPA Substance Registry System: 3,5-Dichloropyrazine-2-carboxyamide(312736-49-5)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 312736-49-5(Hazardous Substances Data)

Usage

General Description

3,5-Dichloropyrazine-2-carboxyamide, also known as DCPC, is a chemical compound with the molecular formula C6H3Cl2N3O. It is a heterocyclic compound that contains two chlorine atoms and a carboxyamide functional group. DCPC is mainly used in the production of pharmaceuticals and agrochemicals, and it is also employed as an intermediate in the synthesis of other organic compounds. Some of its potential uses include its antitumor and antiviral properties, making it an important compound in drug development and research. However, due to its potential toxicity and environmental impact, proper precautions must be taken when handling and disposing of DCPC.

Upstream product

• 768-66-1 2,2,6,6-tetramethyl-piperidine 
• 4774-14-5 2,6-dichloropyrazine 
• 124-38-9 carbon dioxide 

Downstream Products

• 312736-50-8 3,5-dichloropyrazine-2-carboxamide 
• 330786-09-9 3,5-dichloro-pyrazine-2-carboxylic acid methyl ester 
• 1168091-46-0 5-chloro-3-(2-fluoro-4-trimethylsilanyl-phenylamino)-pyrazine-2-carboxylic acid 
• 136866-27-8 3,5-dichloro-pyrazine-2-carbaldehyde 

Relevant articles and documents

UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF

The present application is directed to compounds of Formula (I), (II), (III) or (IV) compositions comprising these compounds, methods for their preparation and their uses, for example, as acyl hydrazone linkers, which can link two chemical entities together for further use as medicaments and/or diagnostics.

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

COMPOUNDS AND METHODS FOR TREATMENT OF CANCER

Compounds for treating, preventing or managing cancer are disclosed. Also provided are methods for using the compounds in treatment of various cancers. Also provided are methods of treatment using the compounds together with another chemotherapy, radiation therapy, hormonal therapy, biological therapy, or immunotherapy. Pharmaceutical compositions suitable for use in the methods are also disclosed.